{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=55&state=Colorado",
    "query": {
      "state": "Colorado",
      "city": "Aurora",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 7459,
    "total_pages": 746,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=56&state=Colorado&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=54&state=Colorado&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:11:48.118Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02912559",
      "title": "Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "DNA Repair Disorder",
        "Lynch Syndrome",
        "Stage III Colon Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 712,
      "start_date": "2017-10-16",
      "completion_date": "2026-12-18",
      "has_results": true,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 1026,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02912559"
    },
    {
      "nct_id": "NCT00709280",
      "title": "Infant Study of Inhaled Saline in Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "7% Hypertonic Saline (HS)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Isotonic Saline (IS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CF Therapeutics Development Network Coordinating Center",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "4 Months to 59 Months"
      },
      "enrollment_count": 321,
      "start_date": "2009-04",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2013-02-12",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00709280"
    },
    {
      "nct_id": "NCT05814627",
      "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 487,
      "start_date": "2023-06-15",
      "completion_date": "2026-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 85,
      "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05814627"
    },
    {
      "nct_id": "NCT00955305",
      "title": "Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Large Cell Lung Carcinoma",
        "Lung Adenocarcinoma",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Stage IV Non-Small Cell Lung Cancer",
        "Bronchioloalveolar Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2010-03",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 165,
      "location_summary": "Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 122 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00955305"
    },
    {
      "nct_id": "NCT03818529",
      "title": "ATHN 8: Previously Untreated Patients (PUPs) Matter Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia",
        "Hemophilia A",
        "Hemophilia B",
        "Hemophilia A With Inhibitor",
        "Hemophilia B With Inhibitor",
        "Haemophilia B Without Inhibitor",
        "Haemophilia A Without Inhibitor",
        "Haemophilia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "American Thrombosis and Hemostasis Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "13 Years",
        "sex": "ALL",
        "summary": "0 Years to 13 Years"
      },
      "enrollment_count": 237,
      "start_date": "2018-10-03",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Madera, California • San Diego, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03818529"
    },
    {
      "nct_id": "NCT03926637",
      "title": "Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Multiple Sclerosis Performance Test (MSPT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3073,
      "start_date": "2019-06-17",
      "completion_date": "2022-12-05",
      "has_results": false,
      "last_update_posted_date": "2023-01-30",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 22,
      "location_summary": "Berkeley, California • Los Angeles, California • Aurora, Colorado + 18 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926637"
    },
    {
      "nct_id": "NCT01272037",
      "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Ductal Carcinoma In Situ",
        "Invasive Breast Carcinoma",
        "Multicentric Breast Carcinoma",
        "Multifocal Breast Carcinoma",
        "Synchronous Bilateral Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Systemic Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5018,
      "start_date": "2011-02-28",
      "completion_date": "2027-01-08",
      "has_results": true,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 1435,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272037"
    },
    {
      "nct_id": "NCT07421700",
      "title": "Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Cancer",
        "Advanced/Metastatic Urothelial Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-08634404",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2026-03-11",
      "completion_date": "2028-09-25",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 164,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 100 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Atascadero",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07421700"
    },
    {
      "nct_id": "NCT07428187",
      "title": "Snacking Effects on the Brain Response to Foods and Satiety During Dieting",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overweight/Obesity"
      ],
      "interventions": [
        {
          "name": "Snack Type 1: Walnuts",
          "type": "OTHER"
        },
        {
          "name": "Snack Type 2: Pretzels",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "25 Years to 45 Years"
      },
      "enrollment_count": 70,
      "start_date": "2026-03-05",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07428187"
    },
    {
      "nct_id": "NCT02213263",
      "title": "A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "PF-05280586",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MabThera®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 394,
      "start_date": "2014-09-30",
      "completion_date": "2018-04-19",
      "has_results": true,
      "last_update_posted_date": "2019-06-20",
      "last_synced_at": "2026-11-19T10:11:48.118Z",
      "location_count": 91,
      "location_summary": "Anaheim, California • Corona, California • Downey, California + 62 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02213263"
    }
  ]
}